Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bayesian optimal designs for Phase I clinical trials.

Linda M Haines1, Inna Perevozskaya, William F Rosenberger

  • 1School of Mathematics, Statistics, and Information Technology, University of Natal Pietermaritzburg, Private Bag X01, Scottsville 3209, South Africa. haines@nu.ac.za

Biometrics
|November 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reliability of bioimpedance spectroscopy in the upper trapezius muscle.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology·2026
Same author

A historical note: Rediscovering an unpublished response to Korn and Freidlin (2011).

Statistical methods in medical research·2026
Same author

Revisiting optimal allocations for binary responses: insights from considering type-I error rate control.

Biometrics·2025
Same author

A Two-Stage Covariate-Adjusted Response-Adaptive Enrichment Design.

Statistics in biopharmaceutical research·2025
Same author

Using Win Odds to Improve Commit-to-Phase-3 Decision-Making in Oncology.

Statistics in medicine·2025
Same author

Exploring Stratification Strategies for Population- Versus Randomization-Based Inference.

Pharmaceutical statistics·2024
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

This study introduces a new Bayesian optimal design for Phase I clinical trials to efficiently find the maximum tolerated dose. The method minimizes the risk of exceeding safe dosage levels, improving patient safety during early drug development.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacometrics

Background:

  • Phase I clinical trials are crucial for determining the maximum tolerated dose (MTD) of new drugs.
  • Traditional methods may not efficiently balance dose-escalation with patient safety.
  • Optimal design theory offers a framework for improving trial efficiency and safety.

Purpose of the Study:

  • To develop a novel Bayesian optimal design for Phase I clinical trials.
  • To efficiently estimate the maximum tolerated dose (MTD) while minimizing the probability of exceeding the maximum acceptable dose.
  • To adapt designs for both continuous and discrete dosing scenarios.

Main Methods:

  • Utilizes constrained Bayesian c- and D-optimal designs rooted in formal optimal design theory.

Related Experiment Videos

  • Implements a constraint to control the probability of exceeding the maximum acceptable dose.
  • Extends the approach to discrete doses and develops a sequential design scheme with a pilot study.

    • Main Results:

    • Presents results for constrained designs on log doses.
    • Provides an associated equivalence theorem for the proposed designs.
    • Simulation studies explore the properties of the Bayesian sequential optimal design scheme.

    Conclusions:

    • The proposed constrained Bayesian optimal designs offer an efficient approach for MTD estimation in Phase I trials.
    • The sequential design scheme is practical for discrete dosing and enhances patient safety.
    • This methodology advances the design of early-phase clinical trials.